Empagliflozin ( DrugBank: Empagliflozin )

5 diseases

ID	Disease name (Link within this page)	Number of trials
65	Primary immunodeficiency	3
72	Pituitary ADH secretion disorder	4
96	Crohn disease	1
97	Ulcerative colitis	1
257	Hepatic glycogenosis	2

65. Primary immunodeficiency

Clinical trials : 482 / Drugs : 653 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05078879 (ClinicalTrials.gov)	November 16, 2021	14/10/2021	Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency	A Phase 1 Study of Empagliflozin as Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency	Crohn's Disease;Glycogen Metabolism;Inflammatory Bowel Disease (IBD)	Drug: Empagliflozin	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Recruiting	18 Years	N/A	All	10	Phase 1	United States
2	NCT04986735 (ClinicalTrials.gov)	August 1, 2021	27/7/2021	Prospective Cohort Study of Children With GSD1b Receiving Empagliflozin	Evaluation of Safety and Efficacy of Empagliflozin for Neutropenia and Neutrophil Dysfunction in Children With Glycogen Storage Disease Type 1b (GSD1b)	Glycogen Storage Disease Type IB	Drug: Empagliflozin	Hong Kong Children's Hospital	NULL	Not yet recruiting	6 Months	18 Years	All	11		NULL
3	EUCTR2018-004191-35-BE (EUCTR)	12/04/2019	05/03/2019	Use of an antidiabetic drug (Empagliflozin) to lower the blood level of 1,5-anhydroglucitol in patients deficient in the glucose-6-phosphate transporter (GSD1b) and the phosphatase G6PC3, both of the endoplasmic reticulum, to treat their recurrent infections by normalizing their blood neutrophil counts. Neutrophils are the most abundant white blood cells in our blood that are essential to help fighting infections. 1,5-anhydroglucitol is a sugar derivative with no known function.	Evaluation of the safety and efficacy of administration of Empagliflozin in a new treatment for neutropenia in patients with Glycogen Storage Disease type 1b (GSD1b) and G6PC3 deficiency. - GLYCO-1B	(1) Severe Congenital Neutropenia type 4 (SNC4) due to a deficiency in G6PC3, a phosphatase of the endoplasmic also known a Ubiquitous glucose-6-phosphatase and (2) the neutropenia in Glycogen Storage Disease type 1b due to a deficiency in the glucose-6-phosphate transporter (G6PT / SLC37A4) of the endoplasmic reticulum.;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]	Trade Name: Jardiance Product Name: Empagliflozin Product Code: A10BK03	Cliniques universitaires Saint-Luc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	5	Phase 4	Belgium

72. Pituitary ADH secretion disorder

Clinical trials : 40 / Drugs : 28 - (DrugBank : 7) / Drug target genes : 5 - Drug target pathways : 9

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04447911 (ClinicalTrials.gov)	February 4, 2021	10/6/2020	Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia	Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia - a Multicentric Randomized Double-blind Placebo-controlled Trial (the EMPOWER Study)	Hyponatremia;SIADH;Liver Failure;Kidney Failure	Drug: Empagliflozin 25 MG;Drug: Placebo	University Hospital, Basel, Switzerland	Luzerner Kantonsspital	Recruiting	18 Years	N/A	All	172	Phase 4	Switzerland
2	NCT03202667 (ClinicalTrials.gov)	December 15, 2017	27/6/2017	Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study	Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study	SIAD - Syndrome of Inappropriate Antidiuresis;Hyponatremia	Drug: Empagliflozin 25mg;Drug: Placebo	University Hospital, Basel, Switzerland	NULL	Completed	18 Years	N/A	All	17	Phase 2/Phase 3	Switzerland
3	NCT02874807 (ClinicalTrials.gov)	September 5, 2016	17/8/2016	Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study	Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study	SIADH	Drug: Empagliflozin;Other: Placebo	University Hospital, Basel, Switzerland	NULL	Completed	18 Years	84 Years	All	88	Phase 2/Phase 3	Switzerland
4	NCT02729766 (ClinicalTrials.gov)	March 2016	24/3/2016	Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study	Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study	Inappropriate ADH Syndrome	Other: Induced hypotonic hyponatremia - SIAD model;Drug: Empagliflozin 25mg Tbl;Drug: Placebo P-Tablet	University Hospital, Basel, Switzerland	NULL	Completed	18 Years	65 Years	Both	15	Phase 2/Phase 3	Switzerland

96. Crohn disease

Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05078879 (ClinicalTrials.gov)	November 16, 2021	14/10/2021	Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency	A Phase 1 Study of Empagliflozin as Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency	Crohn's Disease;Glycogen Metabolism;Inflammatory Bowel Disease (IBD)	Drug: Empagliflozin	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Recruiting	18 Years	N/A	All	10	Phase 1	United States

97. Ulcerative colitis

Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05058417 (ClinicalTrials.gov)	October 1, 2021	16/9/2021	Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis	Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis	Ulcerative Colitis	Drug: Placebo;Drug: Empagliflozin 10 MG	Sadat City University	NULL	Recruiting	18 Years	60 Years	All	50	Phase 2	Egypt

257. Hepatic glycogenosis

Clinical trials : 14 / Drugs : 28 - (DrugBank : 7) / Drug target genes : 3 - Drug target pathways : 8

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04930627 (ClinicalTrials.gov)	July 2021	11/6/2021	Safety and Efficacy of Empagliflozin in GSD1b Patients With Neutropenia	Evaluation of Efficacy and Safety of Empagliflozin in Treatment of Neutropenia in Patients With Glycogenosis Ib	Glucose 6 Phosphatase Deficiency	Drug: Empagliflozin	Children's Memorial Health Institute, Poland	Department of Internal Medicine, Hypertension and Vascular Diseases, The Medical University of Warsaw	Not yet recruiting	N/A	N/A	All	20	Phase 2	Poland
2	NCT04138251 (ClinicalTrials.gov)	June 20, 2019	20/6/2019	Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency	Evaluation of the Safety and Efficacy of Empagliflozin Administration as a Treatment for Neutropenia in Patients With Glycogenosis Type 1b and G6PC3 Deficiency	Glycogen Storage Disease Type I;Glucose 6 Phosphatase Deficiency	Drug: Empagliflozin	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	NULL	Recruiting	1 Year	18 Years	All	5	Phase 2	Belgium